Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model

Journal of Infectious Diseases

Volumn 201, Issue 9, 2010, Pages 1436-1440

  Martinez, Mluis R ^a,b,e   Mihu, Mircea Radu ^a,b   Tar, Moses ^b   Cordero, Radames J B ^a,b   Han, George ^c   Friedman, Adam J ^c,d   Friedman, Joel M ^c,d   Nosanchuk, Joshua D ^a,b  

^a Division of Infectious Diseases   (United States)

^b Department of Microbiology and Immunology ^*  (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e BRONX COMMUNITY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL DAMAGE; CELL VIABILITY; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; CANDIDIASIS; CATHETER INFECTION; CENTRAL VENOUS CATHETERIZATION; DRUG EFFECT; HUMAN;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CHITOSAN; HUMANS; MICROSCOPY, ELECTRON, SCANNING;

EID: 77950949287     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651558     Document Type: Article

References (15)

1. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002;34:1232-1242.
2. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995;21:994-996.
3. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2003;38:161-189.
4. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis 2001;7:277-281.
5. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5: 186-197.
6. Rabea EI, Badawy ME, Stevens CV, Smagghe G, Steurbaut W. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 2003;4:1457-1465. (Pubitemid 37455555)
7. Carlson. RP, Taffs R, Davison. WM, Stewart PS. Anti-biofilm properties of chitosan-coated surfaces. J Biomater Sci Polym Ed 2008; 19:10351046.
8. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004;72:6023-6031.
9. Meshulam T, Levitz SM, Christin L, Diamond RD. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3 ) -bis- (2-methoxy-4-nitro-5-sulphenyl) - (2H) -tetrazolium-5-carboxanilide (XTT). J Infect Dis 1995;172:1153-1156.
10. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008;21:606-625.
11. Miyake Y, Tsunoda T, Minagi S, Akagawa Y, Tsuru H, Suginaka H. Antifungal drugs affect adherence of Candida albicans to acrylic surfaces by changing the zeta-potential of fungal cells. FEMS Microbiol Lett 1990;57:211-214.
12. SavardT,BeaulieuC,BoucherI,ChampagneCP. Antimicrobialactionofhydrolyzedchitosanagainstspoilageyeastsandlacticacidbacte riaoffermentedvegetables.JFoodProt2002;65:828-833.(Pubitemid34494834)
13. Nosanchuk JD, Casadevall A. Cellular charge of Cryptococcus neoformans, contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun 1997;65:1836-1841.
14. Sudarshan NR, Hoover DG, Knorr D. Antibacterial action of chitosan. Food Biotechnol 1992;6:257-272.
15. Jung B, Kim C, Choi K, Lee YM, Kim J. Preparation of amphiphilic chitosan and their antimicrobial activities. J Appl Polym Sci 1999; 72: 1713-1719.